Physician profile
Vikram M Atit
NPI 1871560904
$65,190.69
in general payments reported to CMS, 2019-2025
76 companies · $3,707 in 2025
The $3,707 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $7,921 · 2020: $12K · 2021: $20K · 2022: $13K · 2023: $5,095 · 2024: $3,108 · 2025: $3,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,686.07 |
| Education | $225.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,926.68 | 2020-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $9,630.19 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $3,831.02 | 2019-2022 | |
| Sk Life Science, INC. | $3,744.18 | 2020-2025 | Xcopri |
| Biohaven Pharmaceutical Holding Company LTD. | $2,776.10 | 2022 | |
| Ucb, INC. | $2,341.68 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $2,170.35 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $2,009.54 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $1,824.09 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $1,577.45 | 2019-2025 | Aimovig, Uplizna |
| Eisai INC. | $1,422.09 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,355.81 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $1,153.59 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $1,026.84 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Amneal Pharmaceuticals LLC | $919.34 | 2019-2025 | Crexont, Rytary, Lyvispah |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $885.96 | 2021-2025 | Zeposia |
| Biogen, INC. | $831.80 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Pfizer INC. | $811.33 | 2019-2025 | |
| Octapharma USA, INC. | $765.30 | 2021-2025 | Panzyga, Cutaquig |
| Csl Behring | $728.53 | 2019-2024 | Hizentra |
| Acorda Therapeutics, INC | $727.21 | 2019-2023 | Inbrija |
| Janssen Pharmaceuticals, INC | $684.07 | 2020-2023 | Ponvory |
| Biohaven Pharmaceuticals, INC. | $670.92 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $668.17 | 2019-2024 | Epidiolex, Xywav |
| Adamas Pharmaceuticals, INC. | $656.11 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $627.28 | 2019-2022 | |
| Genzyme Corporation | $597.20 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $560.24 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $509.01 | 2019-2025 | Nuplazid |
| Kyowa Kirin, INC. | $444.18 | 2020-2024 | Nourianz |
| Lundbeck LLC | $427.56 | 2020-2025 | Vyepti, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $416.54 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $367.46 | 2023-2024 | Nuedexta, Rexulti |
| Impel Pharmaceuticals INC. | $362.80 | 2022-2023 | Trudhesa |
| Tg Therapeutics, INC. | $317.25 | 2023-2025 | |
| Mdd US Operations, LLC | $272.43 | 2022-2025 | Gocovri, Gocovri |
| Argenx US, INC. | $234.09 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $231.49 | 2022-2023 | Ocrevus |
| Mallinckrodt Hospital Products INC. | $231.09 | 2021-2025 | Acthar |
| Zyla Life Sciences, INC. | $173.20 | 2019-2020 | |
| Tanabe Pharma America, INC. | $159.91 | 2023-2025 | Radicava |
| Upsher-Smith Laboratories LLC | $158.82 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.11 | 2021-2025 | Hyqvia |
| Sumitomo Pharma America, INC. | $145.13 | 2023 | Aptiom |
| Azurity Pharmaceuticals, INC. | $111.21 | 2023-2024 | Horizant, Horizant |
| Corium, LLC | $108.05 | 2022-2023 | Adlarity |
| Janssen Biotech, INC. | $102.73 | 2025 | |
| Sanofi-Aventis U.S. LLC | $102.30 | 2020 | |
| Nevro Corp. | $102.16 | 2022-2024 | Senza |
| Horizon Therapeutics Plc | $99.53 | 2022-2023 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $90.20 | 2022-2024 | Fycompa |
| Greenwich Biosciences, INC. | $80.22 | 2019-2021 | |
| Neurelis, INC. | $66.30 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $61.02 | 2020-2022 | |
| Impel Pharmaceuticals LLC | $60.01 | 2025 | Trudhesa |
| Merck Sharp & Dohme LLC | $57.38 | 2021-2022 | |
| Avion Pharmaceuticals | $56.89 | 2022-2023 | Dhivy |
| Portola Pharmaceuticals, LLC | $55.53 | 2019 | |
| Banner Life Sciences, LLC | $55.44 | 2022-2023 | |
| Ge Healthcare | $51.40 | 2019-2025 | |
| Livanova USA, INC. | $47.09 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $42.93 | 2023 | Ztlido |
| Xeris Pharmaceuticals, INC. | $36.91 | 2022-2024 | Keveyis |
| Harmony Biosciences LLC | $36.02 | 2022 | |
| Ceribell, INC. | $35.18 | 2021 | |
| Merz Pharmaceuticals, LLC | $32.74 | 2025 | Xeomin, Inbrija |
| Boston Scientific Corporation | $32.38 | 2023-2024 | |
| Axsome Therapeutics, INC. | $28.29 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $27.40 | 2021-2023 | Evusheld |
| Si-Bone, INC. | $22.04 | 2024 | |
| Grifols USA, LLC | $20.20 | 2024 | Gamunex-C |
| Bausch Health US, LLC | $13.98 | 2020 | |
| Ani Pharmaceuticals, INC. | $12.95 | 2022 | |
| Life Molecular Imaging LTD | $11.07 | 2023 | Neuraceq |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$743.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Atit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.